- Home
- AEON vs FEMY Comparison
AEON vs FEMY Comparison
Compare AEON & FEMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AEON | FEMY |
|---|---|---|
| Founded | N/A | 2004 |
| Country | United States | United States |
| Employees | 8 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.8M | 23.2M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | AEON | FEMY |
|---|---|---|
| Price | $0.92 | $0.47 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $7.20 | $5.50 |
| AVG Volume (30 Days) | 122.6K | ★ 363.1K |
| Earning Date | 05-14-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 44.71 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,293,313.00 |
| Revenue This Year | N/A | $105.16 |
| Revenue Next Year | N/A | $200.23 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 40.77 |
| 52 Week Low | $0.43 | $0.31 |
| 52 Week High | $1.45 | $1.16 |
Technical Indicators
Market Signals| Indicator | AEON | FEMY |
|---|---|---|
| Relative Strength Index (RSI) | 42.62 | 61.01 |
| Support Level | $0.91 | $0.33 |
| Resistance Level | $1.12 | $0.58 |
| Average True Range (ATR) | 0.08 | 0.03 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 15.63 | 94.53 |
Price Performance
Historical ComparisonAbout AEON AEON Biopharma Inc.
AEON Biopharma Inc is a biopharmaceutical company focused on the development of ABP-450 (prabotulinumtoxinA), a biosimilar to Botox (onabotulinumtoxinA), for therapeutic indications. The company is advancing ABP-450 through the biosimilar regulatory pathway and holds development and commercialization rights across multiple international markets.
About FEMY Femasys Inc.
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.